文献速递心脑血管急症复苏、休克与脓毒症

CULPRIT-SHOCK试验中不同心电图表现的心肌梗死相关心源性休克的临床结局:仅罪犯病变PCI与多支血管PCI的比较

Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial.
PubMed 文献 · Chest · 2020-11-26
一句话结论心源性休克中,NSTEMI和LBBBMI患者风险特征虽高于STEMI,但心电图表现并非独立死亡危险因素,且不影响血运重建策略疗效,支持仅罪犯病变PCI作为首选策略。

该研究基于CULPRIT-SHOCK试验,分析665例心源性休克患者,按心电图表现分为STEMI(55.9%)、NSTEMI(29.3%)和LBBBMI(14.7%)。NSTEMI和LBBBMI患者年龄更大、心血管危险因素和造影严重程度不同,但校正后30天和1年死亡风险与STEMI无显著差异。提示心电图表现不改变治疗策略选择,仅罪犯病变PCI across AMI spectrum均适用。

要点

  • 在心源性休克患者中,NSTEMI和LBBBMI与STEMI相比,校正后30天死亡风险无显著差异(NSTEMI vs STEMI aOR 1.05,95%CI 0.66-1.67;LBBBMI vs STEMI aOR 1.31,95%CI 0.73-2.34)。
  • 1年死亡风险校正后亦无显著差异(NSTEMI vs STEMI aOR 1.21,95%CI 0.76-1.92;LBBBMI vs STEMI aOR 1.59,95%CI 0.89-2.84)。

适用人群与场景

  • CULPRIT-SHOCK试验中的心源性休克患者,均接受PCI治疗,按心电图表现分为STEMI、NSTEMI和LBBBMI三组。

诊断标准与关键阈值

  • 心电图表现分类:STEMI、NSTEMI、LBBBMI(左束支传导阻滞型心肌梗死),依据原文定义。

处置流程与药物剂量

  • 血运重建策略:仅罪犯病变PCI vs 多支血管PCI,心电图表现不影响策略选择,支持仅罪犯病变PCI作为首选。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:基于CULPRIT-SHOCK试验的回顾性分析,样本量665例,多中心。
  • 人群:心源性休克患者,STEMI 55.9%,NSTEMI 29.3%,LBBBMI 14.7%。
  • 干预与对照:仅罪犯病变PCI vs 多支血管PCI。
  • 不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:基于随机对照试验CULPRIT-SHOCK的二次分析(回顾性分析)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:原文未明确说明,但设计为事后分析,可能存在选择偏倚和未测量混杂。

对床旁实践的改变

  • 对于心源性休克患者,无论心电图表现为STEMI、NSTEMI还是LBBBMI,血运重建策略应首选仅罪犯病变PCI,因为心电图表现不影响治疗效应。
  • NSTEMI和LBBBMI患者风险特征更高(年龄更大、危险因素更多),但校正后死亡风险与STEMI无显著差异,提示不应仅凭心电图表现判断预后或改变策略。
  • 常见陷阱:不能因NSTEMI或LBBBMI而延迟或改变血运重建策略,证据支持仅罪犯病变PCI across AMI spectrum。

指南或共识出处

  • CULPRIT-SHOCK试验(原文未提供具体指南或共识名称)

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: The impact of ECG presentations of acute myocardial infarction (AMI) in cardiogenic shock is unknown.

RESEARCH QUESTION: In myocardial infarction with cardiogenic shock, is there a difference in the outcomes and effect of revascularization strategies between non-ST-segment elevation myocardial infarction (NSTEMI) and left bundle branch block myocardial infarction (LBBBMI) vs ST-segment elevation myocardial infarction (STEMI)?

STUDY DESIGN AND METHODS: Cardiogenic shock patients from the CULPRIT-SHOCK trial with NSTEMI or LBBBMI were compared with STEMI patients for 30-day and 1-year all-cause mortality. The interaction between ECG presentation and the effect of revascularization strategies on outcomes was evaluated.

RESULTS: Of 665 cardiogenic shock patients analyzed, 55.9% demonstrated STEMI, 29.3% demonstrated NSTEMI, and 14.7% demonstrated LBBBMI. Patients differed in mean age (68.0 years in STEMI patients, 71.0 years in NSTEMI patients, and 73.5 years in LBBBMI patients; P = .015), cardiovascular risk factors, and angiographic severity. No difference was found in the 30-day risk of death between NSTEMI and STEMI patients (48.7% vs 43.0%; adjusted OR [aOR], 1.05; 95% CI, 0.66-1.67; P = .85), nor between LBBBMI and STEMI patients (59.2% vs 43.0%; aOR, 1.31; 95% CI, 0.73-2.34; P = .36). Although the univariate risk of death by 1 year was higher in NSTEMI and LBBBMI patients compared with STEMI patients, ECG presentation was not an independent risk factor of mortality after adjustment (NSTEMI vs STEMI: 56.4% vs 46.8%; aOR, 1.21; 95% CI, 0.76-1.92; P = .42; LBBBMI vs STEMI: 69.4% vs 46.8%; aOR, 1.59; 95% CI, 0.89-2.84; P = .12). ECG presentation did not modify the effect of the revascularization strategy on 30-day and 1-year mortality (P = .91 and P = .97 for interaction).

INTERPRETATION: In patients with cardiogenic shock, NSTEMI and LBBBMI presentations reflect higher-risk profiles than STEMI presentations, but are not independent risk factors of mortality. ECG presentations did not modify the treatment effect, supporting culprit-lesion-only percutaneous coronary intervention as the preferred strategy across the AMI spectrum.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Zeitouni M, Akin I, Desch S, et al. Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial. Chest. 2020. PMID: 33248059. doi:10.1016/j.chest.2020.10.089

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。